Susan A. Witham

Catalent JNP, Inc. engages in the research and development of drugs and therapeutics. It offers analytical characterization and pre-formulation testing; formulation development; and clinical manufacturing of capsules and tablets. The company was founded in December 1986 and is headquartered in Somerset, NJ.

Adams Respiratory Therapeutics, Inc. manufactures over-the-counter remedies for respiratory ailments. The company's products include Mucinex, Mucinex DM, Maximum Strength Mucinex, Mucinex DM, Mucinex D, and the Delsym. It is a subsidiary of Reckitt Benckiser Corp. Adams Respiratory Therapeutics is headquartered in Chester, NJ

Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ.

Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.

Part of Kenvue, Inc., Johnson & Johnson Consumer Products Co. develops and markets baby care, wound care, and skin care products. Jorge S. Mesquita has been the CEO of the American company since 2014.

Kremers Urban Pharmaceuticals, Inc. operates as a generic pharmaceutical company. It brands include Aciphex, Colyte, Concerta, Imdur, Lipitor, Monoket and Verelan. The firm provides atorvastatin calcium tablets, hydrocodone polistirex and chlorpheniramine polistirex pennkinetic extended-release tablets. The company was founded in 1904 and is headquartered in Princeton, NJ.

Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019.